MMP9 Antibody / Matrix metalloproteinase-9

Immunohistochemistry (FFPE): 0.5-1ug/ml for 30 min at RT

The stated application concentrations are suggested starting points. Titration of the MMP9 antibody may be required due to differences in protocols and secondary/substrate sensitivity.

1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

May play an essential role in local proteolysis of the extracellular matrix and in leukocyte migration. Could play a role in bone osteoclastic resorption. Cleaves KiSS1 at a Gly-|-Leu bond. Cleaves type IV and type V collagen into large C-terminal three quarter fragments and shorter N-terminal one quarter fragments. Degrades fibronectin but not laminin or Pz-peptide.

In the arthritis patient this enzyme might contribute to the pathogenesis of joint destruction and might constitute a useful marker of disease status. [UniProt]

Purified

1 mg/ml in 1X PBS; BSA free, sodium azide free

Amino acids 603-614 were used as the immunogen for the recombinant MMP9 antibody.

This recombinant MMP9 antibody is available for research use only.

Cytoplasmic, nuclear, secreted

Protein G affinity chromatography

P14780